Navivumab/Firivumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameNavivumab/Firivumab
Drug Alias NameUniversal influenza antibody - CelltrionCT-P27
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInfluenza virus hemagglutinin glycoproteins inhibitors
TargetsInfluenza virus hemagglutinin glycoproteins
Therapy Area/IndicationsInfluenza A virus infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsYes
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCelltrion Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCelltrion Inc
Active IndicationsN/A
Inactive IndicationsInfluenza A virus infections

Other Information

ATC CodeN/A
Related LinksN/A